Bristol-Myers Squibb announces FDA approval of dditional indication for Opdivo (nivolumab)
Bristol-Myers Squibb announced the FDA has approved Opdivo (nivolumab) injection for treatment of patients with metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. Opdivo is a PD-1 (programmed death receptor-1) therapy. March 04, 2015